Adam Siebert & Jeff Holder: early investment in manufacturing is critical for CGT accessibility

https://is1-ssl.mzstatic.com/image/thumb/Podcasts125/v4/8e/18/68/8e1868dc-f19d-0a3b-5c97-f0aceede2b43/mza_15123957094614483735.jpg/600x600bb.jpg

Ori Spotlight

Ori Biotech

49 episodes

46 minutes ago

Ori Spotlight covers the latest in cell and gene therapy. Jason C. Foster, Ori Biotech CEO will be talking to leaders from across the industry to find out more about how we can break down the barriers and seize the opportunities to make sure that every patient has access to life-changing treatments. Connect with Ori Biotech to learn more about partnering to pioneer innovative technologies in CGT manufacturing that bring CGT products to market at commercial scale at decreased costs while increasing throughput and improving quality: www.oribiotech.com/connect

Life Sciences

Science

RSS

All content for Ori Spotlight is the property of Ori Biotech and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.

Life Sciences

Science

https://d3t3ozftmdmh3i.cloudfront.net/staging/podcast_uploaded_episode/14589339/14589339-1708366836303-c341783f78bce.jpg

Adam Siebert & Jeff Holder: early investment in manufacturing is critical for CGT accessibility

Ori Spotlight

1 hour 5 minutes 33 seconds

1 year ago

Adam Siebert & Jeff Holder: early investment in manufacturing is critical for CGT accessibility

In this episode of the Ori Spotlight Podcast, host Jason C. Foster is joined by Jeff Holder and Adam Siebert from LEK Consulting, who offer an in-depth exploration of the evolving cell and gene therapy (CGT) industry. LEK Consulting, a global leader in strategic advisory, aims to address the critical challenges of scalability and commercial viability within the CGT sector. Jeff and Adam, with their extensive background in life sciences consulting, share their insights on the importance of early investment in manufacturing processes to ensure that groundbreaking therapies can be delivered to patients efficiently and on a large scale. Together they explore the intricacies of CGT production, the significance of early-stage manufacturing considerations, and their vision for making advanced therapies more accessible to those in need. Learn more about: Jeff Holder - https://www.linkedin.com/in/jeff-holder-ph-d-7a391087 Adam Siebert - https://www.linkedin.com/in/adam-siebert-8772b327/